UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an ...

Tenpoint Therapeutics and Visus Therapeutics have merged to focus on aging-related ocular conditions, with key products ...

Private biotech Tenpoint emerged in 2023 with $70 million and a regenerative medicine platform. The company was previously ...

Tenpoint Therapeutics, Limited ("Tenpoint") and Visus Therapeutics, Inc., ("Visus") announce today the completion of their ...